Changes in plasma concentrations of edoxaban and coagulation biomarkers according to thromboembolic risk and atrial fibrillation type in patients undergoing catheter ablation: Subanalysis of KYU-RABLE.
Tetsuji ShinoharaNaohiko TakahashiYasushi MukaiTetsuya KimuraKeita YamaguchiAtsushi TakitaHideki OrigasaKen Okumuranull nullPublished in: Journal of arrhythmia (2020)
The changes in plasma concentrations of edoxaban and coagulation biomarkers in each subgroup were similar to those of the whole analysis, regardless of the thromboembolic risk (CHADS2 <2 or ≥2) or AF type (PAF or non-PAF).